[Renal sequelae of sympathetic hyperactivity].
Watschinger
Bruno
B
Klinische Abteilung für Nephrologie und Dialyse der Universitätsklinik für Innere Medizin III, Wien, Osterreich.
Habicht
Antje
A
D058647:Adrenergic alpha-2 Receptor Agonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D006977:Hypertension, Renal / Q000188:drug therapy / Q000503:physiopathology; D006978:Hypertension, Renovascular / Q000188:drug therapy / Q000503:physiopathology; D007031:Hypothalamus / Q000503:physiopathology; D054755:Imidazoline Receptors; D007668:Kidney / Q000294:innervation*; D009638:Norepinephrine / Q000097:blood; D011955:Receptors, Drug / Q000819:agonists; D051437:Renal Insufficiency / Q000188:drug therapy / Q000503:physiopathology*; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D016896:Treatment Outcome
D058647:Adrenergic alpha-2 Receptor Agonists; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D054755:Imidazoline Receptors; D011955:Receptors, Drug; C410887:imidazoline I1 receptors; D000804:Angiotensin II; D012083:Renin; D003000:Clonidine; D009638:Norepinephrine